Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

Key Inclusion Criteria: * Liver biopsy consistent with NASH and cirrhosis (F4 fibrosis) according to the NASH Clinical Research Network (CRN) classification, in the opinion of the central reader * Has the following laboratory parameters at the screening visit, as determined by the central laboratory: * Alanine aminotransferase (ALT) ≤ 8 x upper limit of normal (ULN) * Creatinine Clearance (CLcr) ≥ 30 milliliter/minute (mL/min), as calculated by the Cockcroft-Gault equation * HbA1c ≤ 9.5% (or serum fructosamine ≤ 381 micromole (μmol) if HbA1c is unable to be resulted) * International normalised ratio (INR) ≤ 1.4, unless due to therapeutic anti-coagulation * Platelet count ≥ 100,000/μL Key Exclusion Criteria: * Prior history of decompensated liver disease including clinical ascites, hepatic encephalopathy (HE), or variceal bleeding * Child-Pugh (CP) score \> 7, as determined at screening, unless due to therapeutic anti-coagulation * Model for End-stage Liver Disease (MELD) score \> 12, as determined at screening, unless due to therapeutic anti-coagulation * Other causes of liver disease including, but not limited to, alcoholic liver disease, hepatitis B, hepatitis C, autoimmune disorders, drug-induced hepatotoxicity, Wilson disease, iron overload, and alpha-1-antitrypsin deficiency, based on medical history and/or centralized review of liver histology. * History of liver transplantation * Current or history of hepatocellular carcinoma (HCC) Note: Other protocol defined Inclusion/Exclusion criteria may apply.